# Sympathomimetic Toxicity

Recognize the hyperadrenergic syndrome early, stabilize agitation and hyperthermia with GABAergic sedation and cooling, then selectively investigate cardiac, neurologic, renal, and muscle complications that determine monitored versus critical-care disposition.

**Clinical question:** How should physicians stabilize, evaluate, and disposition patients with acute sympathomimetic toxicity?

Updated: 2026-09-16T00:10:01.558093+00:00

## What matters in practice
- Treat clinically apparent sympathomimetic toxicity immediately; benzodiazepines are first-line for neuroexcitation and hyperadrenergic manifestations. [14][21]
- Hyperthermia, severe agitation, seizures, chest pain, rhabdomyolysis, acute kidney injury, and intracranial hemorrhage identify patients needing emergency investigation and treatment. [2][13]
- Use ECG and cardiac biomarkers when chest pain, concerning cardiovascular findings, or heavy/long-term stimulant exposure raises concern for ischemia or dysrhythmia. [2][17][18]
- Lower the threshold for CK testing in patients with heavy stimulant exposure or examination findings concerning for rhabdomyolysis; assess renal injury concurrently. [18]
- Toxicology testing is useful only when it changes management, such as differentiating stimulant-associated psychosis from primary psychiatric decompensation or evaluating possible pediatric exposure. [18]

## Stabilize hyperadrenergic toxicity before confirming the exposure

Escalate care according to agitation, temperature, neurologic status, and end-organ injury rather than the reported substance.

Use an ABC assessment and immediately obtain temperature, heart rate, blood pressure, respiratory status, and serial mental-status examinations. The clinically useful syndrome is autonomic hyperactivity—tachycardia, hypertension, diaphoresis, and mydriasis—with psychomotor agitation, paranoia, psychosis, seizure, or hyperthermia. Continue vital-sign monitoring, particularly heart rate and blood pressure, because untreated hyperadrenergic physiology can produce complications. [1][21]

Place patients with significant hyperadrenergic manifestations in an acute-care setting. Remove further exposure, minimize stimulation in a quiet area when feasible, and treat neuroexcitation and autonomic instability rather than attempting to establish a specific stimulant diagnosis before treatment. [14][19][21]

Administer a GABAergic agent for stimulant-related hyperadrenergic symptoms; benzodiazepines are the recommended first-line class and also address agitation and seizures. Phenobarbital or propofol are GABAergic alternatives in appropriate monitored settings. The search results support lorazepam 2 mg orally as one cited option for stimulant intoxication, but do not establish a universal intravenous dosing regimen; titrate the sedative strategy to clinical control with respiratory monitoring. [19][21]
- Treat seizures as a toxicologic emergency with benzodiazepines; do not defer treatment for toxicology confirmation. [19][21]
- Start active cooling when hyperthermia is present; cooling is a core first-line measure alongside benzodiazepines for sympathomimetic toxicity. [14]
- Escalate immediately for severe agitation, hyperthermia, chest pain, seizure, focal neurologic findings, declining consciousness, or evidence of rhabdomyolysis or acute kidney injury. [2][13]

*Immediate features that change the initial care setting and diagnostic priority. [2][13][21]*

| Presentation | Immediate action | Priority complication |
| --- | --- | --- |
| Marked agitation, paranoia, or psychosis with tachycardia or hypertension | Continuous vital-sign observation; benzodiazepine-first GABAergic treatment in an acute-care setting. [21] | Persistent hyperadrenergic injury or stimulant-associated psychosis. [18][21] |
| Hyperthermia | Initiate cooling and control neuroexcitation with benzodiazepines. [14][21] | Severe systemic toxicity requiring emergency treatment. [2][13] |
| Seizure or depressed consciousness | Treat seizure with benzodiazepines; repeat neurologic and respiratory assessment. [19] | Intracranial hemorrhage, co-ingestion, aspiration, or recurrent seizure. [13][19] |
| Chest pain or clinically concerning cardiovascular findings | Obtain ECG and cardiac biomarkers as indicated. [2] | Myocardial ischemia or dysrhythmia. [17][20] |
| Myalgias, rigidity, prolonged agitation, or heavy stimulant exposure | Obtain CK with renal assessment; maintain heightened suspicion for rhabdomyolysis and renal injury. [18] | Rhabdomyolysis and acute kidney injury. [13][18] |

## Target testing to end-organ toxicity and meaningful alternatives

The toxidrome directs treatment; tests determine complications, co-ingestions, and alternative diagnoses.

Obtain point-of-care glucose when altered mental status, seizure, or an uncertain toxidrome makes hypoglycemia a competing diagnosis. In patients with suspected stimulant toxicity, blood chemistries, ECG, cardiac biomarkers, chest radiography, and definitive blood or urine testing may be indicated according to the presentation rather than ordered routinely. [2][19]

For chest pain, ischemic ECG changes, dysrhythmia, persistent hemodynamic abnormalities, or substantial stimulant exposure, obtain an ECG and cardiac biomarkers. Cocaine can cause coronary vasoconstriction while increasing cardiac workload; ECG alone may not establish ischemia, whereas cardiac troponins improve diagnostic clarity. Cocaine also increases dysrhythmia risk, including ventricular tachycardia, and may prolong QRS and QT through sodium- and potassium-channel effects. [17][20][24]

For methamphetamine-associated presentations, consider CBC, comprehensive chemistry panel, troponin, BNP, CK, and urinalysis when the presentation suggests cardiac, renal, or muscle injury. In long-term or heavy stimulant use, maintain heightened suspicion for cardiac and renal disorders, use a lower threshold for ECG, and use a lower threshold for CK when history or examination suggests rhabdomyolysis. [15][18]
- Obtain chest radiography in coma or respiratory compromise when aspiration pneumonia is a concern. [19]
- Interpret QRS or QTc abnormalities as a clue to cardiotoxic co-ingestion rather than as a defining finding of uncomplicated stimulant intoxication. [19]
- Do not use urine toxicology merely to confirm an obvious stimulant toxidrome if the result will not alter care. [18]
- Use comprehensive toxicology testing when the result changes a high-consequence decision, including suspected pediatric exposure or distinction between stimulant-associated psychosis and primary psychiatric decompensation. [18]

### Neurologic and psychiatric branch

Agitated delirium, hallucinations, paranoia, confusion, and formication can occur with cocaine and other stimulants, but focal deficits, persistent depressed consciousness, severe headache, or seizure should redirect evaluation toward intracranial pathology, including hemorrhage. Methamphetamine toxicity may present with seizures and intracranial hemorrhage; serial neurologic assessment is therefore a disposition-critical part of reassessment after initial sedation. [13][19]
- If neurologic findings fail to improve as hyperadrenergic activity is controlled, pursue an alternative neurologic diagnosis rather than attributing persistent deficits to intoxication alone. [13][19]

### Muscle and renal branch

Order CK and renal studies when prolonged agitation, hyperthermia, weakness, or other clinical features raise concern for rhabdomyolysis. A normal initial appearance should not eliminate concern in heavy stimulant use: ASAM/AAAP recommends a lower threshold for CK testing and heightened suspicion for renal disorders based on history and examination. [13][18]
- Use serial clinical reassessment and renal monitoring when CK elevation, renal dysfunction, or ongoing hyperthermia is identified. [13][18]

*Testing should answer a complication or differential-diagnosis question, not simply document exposure. [2][18][19]*

| Clinical trigger | Test | Result that changes next action |
| --- | --- | --- |
| Altered mental status or seizure with uncertain cause | Point-of-care glucose. [19] | Hypoglycemia redirects immediate management away from isolated stimulant toxicity. [19] |
| Chest pain, ischemic symptoms, dysrhythmia, or significant cardiovascular findings | ECG and cardiac biomarkers. [2][17] | Ischemic or conduction findings require cardiac-focused monitoring and evaluation. [17][20] |
| Heavy/long-term stimulant exposure or concerning examination | ECG; consider CK and renal evaluation. [18] | Abnormal ECG, rhabdomyolysis, or renal injury increases monitoring and disposition needs. [18] |
| Coma or respiratory compromise | Chest radiograph. [19] | Aspiration pneumonia becomes a competing or coexisting diagnosis. [19] |
| Psychosis with uncertain stimulant exposure or possible pediatric ingestion | Comprehensive toxicology testing when clinically consequential. [18] | Clarifies a diagnosis or exposure scenario that changes safety and diagnostic decisions. [18] |

## Treat cardiovascular and thermal injury as end-organ toxicity

Persistent abnormalities after sedation require focused evaluation for ischemic, electrical, vascular, and systemic injury.

Treat agitation and autonomic activation first with a benzodiazepine-centered GABAergic strategy, then reassess heart rate, blood pressure, temperature, chest pain, and ECG. This sequence matters because psychomotor agitation and catecholaminergic activation are major drivers of the tachycardia and hypertension seen with sympathomimetic agents. [1][14][21]

Do not dismiss chest pain because the patient is young or reports cocaine use. Cocaine-associated myocardial ischemia can occur in young men without major atherosclerosis, although risk is greater with atherosclerosis and cigarette smoking. Cocaine also roughly doubles the risk of ischemic and hemorrhagic stroke and is associated with aortic dissection; chest, back, or neurologic symptoms therefore require organ-specific evaluation rather than reassurance after initial sedation. [17]

For methamphetamine, consider both acute ischemic/electrical complications and chronic structural disease. In one retrospective cohort, only 28.3% of methamphetamine users had a normal ECG; QTc greater than 440 ms occurred in 27.2%, and a retrospective analysis of 627 ECGs found evidence of myocardial infarction in 6.5%. These data support a low threshold for ECG in high-risk presentations but do not replace symptom- and examination-directed interpretation. [20][18]
- Avoid relying on a single ECG to exclude cocaine-related ischemia when clinical concern remains; integrate serial clinical assessment and cardiac biomarkers. [17]
- Monitor temperature carefully in stimulant toxicity; ketamine may potentiate cocaine cardiovascular toxicity. [8]
- Consider co-ingestion when the clinical picture includes nystagmus, marked coma, atypical respiratory depression, or QRS/QTc abnormalities. Nystagmus can occur with ethanol, benzodiazepines, anticonvulsants, ketamine, dextromethorphan, phencyclidine, and serotonin syndrome. [1][19]

### Beta-blocker controversy

Recommendations in the cited literature differ. A cocaine intoxication overview advises avoiding beta-blocking agents because of concern for unopposed alpha-adrenergic effects, whereas an archived methamphetamine review reports no published cases of unopposed alpha stimulation with beta-blocker treatment and notes that the historical dogma arose from seven cocaine cases. In an acutely hyperadrenergic patient, prioritize benzodiazepine-centered treatment and obtain toxicology or cardiovascular consultation before selecting a beta-blocker strategy for persistent instability. [12][15][21]

*Features that should prevent attribution of all findings to uncomplicated intoxication. [13][17][19][20]*

| Finding | Complication to prioritize | Next diagnostic action |
| --- | --- | --- |
| Chest pain, ischemic symptoms, or concerning ECG | Coronary ischemia or stimulant-related dysrhythmia. [17][20] | ECG and cardiac biomarkers; continue cardiac-focused reassessment. [2][17] |
| Neurologic deficit, severe headache, seizure, or persistent altered consciousness | Intracranial hemorrhage or other neurologic pathology. [13][17] | Repeat neurologic examinations and evaluate for intracranial disease. [13][19] |
| Hyperthermia with severe agitation | Escalating systemic toxicity and rhabdomyolysis. [13][14] | Cooling, benzodiazepine-centered control, CK, and renal assessment. [14][18] |
| Prolonged QRS or QTc | Cardiotoxic co-ingestion or stimulant-related conduction toxicity. [19][20] | Review exposures and maintain ECG-based monitoring. [19] |

## Disposition after physiologic control and complication screening

Disposition should follow repeated reassessment, not the initial degree of agitation alone.

Continue acute-care monitoring until the hyperadrenergic state is controlled and the trajectory of temperature, heart rate, blood pressure, neurologic status, and any identified cardiac, renal, or muscle complication is clear. Significant hyperadrenergic symptoms typically require acute-care management, and serial vital signs are specifically recommended to reduce preventable complications. [21]

Use a higher level of care when severe agitation requires ongoing sedative treatment, hyperthermia persists, seizures recur, chest pain or ECG/troponin findings suggest cardiac injury, neurologic findings raise concern for hemorrhage, or CK/renal testing identifies rhabdomyolysis or acute kidney injury. These presentations are specifically identified among the serious complications of methamphetamine and stimulant toxicity. [2][13][18]

After acute stabilization, assess co-occurring psychiatric conditions and offer treatment for stimulant use disorder. Contingency management, cognitive behavioral therapy, motivational interviewing, the Matrix model, and community reinforcement are core treatment approaches; pharmacotherapy evidence remains limited and is generally considered in specialist care settings. [2]
- Do not treat a positive toxicology test as a substitute for evaluating chest pain, seizure, focal deficits, hyperthermia, or renal injury. [2][13][18]
- When psychosis is present, determine whether symptoms resolve with intoxication treatment and use toxicology testing selectively when distinguishing stimulant-associated psychosis from primary psychiatric decompensation changes management. [18]
- For recurrent presentations or chronic use, maintain suspicion for cardiomyopathy, heart failure, hypertension, ischemia, and injection-related endocarditis when symptoms or examination suggest those diagnoses. [15][23]

*Disposition anchors after initial control of the toxidrome. [2][13][18][21]*

| Clinical course | Disposition implication | Required reassessment |
| --- | --- | --- |
| Persistent hyperthermia, severe agitation, or recurrent seizure | Continue acute-care management and consider critical-care escalation. [2][13][21] | Serial temperature, neurologic status, respiratory status, and vital signs. [19][21] |
| Chest pain, abnormal ECG, or elevated cardiac biomarkers | Cardiac-focused monitored evaluation. [2][17] | Symptoms, ECG, and cardiac biomarker trajectory. [2][17] |
| CK elevation, renal dysfunction, or suspected rhabdomyolysis | Ongoing monitoring for renal and muscle complications. [13][18] | Renal studies, CK, and clinical status. [18] |
| Resolved hyperadrenergic findings with no identified end-organ complication | Consider discharge only after repeated clinical reassessment and linkage to substance-use and psychiatric care. [2][21] | Mental status, vital signs, and ability to engage in safe follow-up. [2][21] |

## Common questions

### Should a urine drug screen be obtained in every suspected sympathomimetic toxidrome?

No. Obtain toxicology testing when it changes a consequential decision, such as suspected pediatric exposure or distinguishing stimulant-associated psychosis from primary psychiatric illness; it is unnecessary to confirm an obvious toxidrome when treatment would be unchanged. [18]

### What ECG findings should raise concern for complications or co-ingestion?

Ischemic changes, dysrhythmia, QRS prolongation, or QTc prolongation warrant cardiac-focused evaluation. QRS or QTc abnormalities may indicate cardiotoxic co-ingestion, while cocaine can impair conduction through sodium- and potassium-channel effects. [17][19][20]

## References
1. Toxidromes and a general approach to poisoning — adc.bmj.com — https://adc.bmj.com/content/110/9/681
2. Amphetamine and methamphetamine use disorder — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-us/201
3. Amphetamine toxicity: Experience with 127 cases - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/0736467989902631
4. Comprehensive review of cardiovascular toxicity of drugs and ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1002%2Fmed.21476
5. Antipsychotics for the treatment of sympathomimetic toxicity — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0735675719300014
6. Human psychobiology of MDMA or 'Ecstasy': an overview of 25 ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1002/hup.2318
7. Substance Abuse and Violence - Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/abs/10.1002/9781118832202.ch29
8. Poisoning with illicit substances: toxicology for the anaesthetist - Wong — associationofanaesthetists-publications.onlinelibrary.wiley.com — https://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/10.1111/anae.12053
9. Mephedrone, compared with MDMA (ecstasy) and amphetamine ... — bpspubs.onlinelibrary.wiley.com — https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/j.1476-5381.2011.01499.x
10. Protection against d-amphetamine toxicity - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/0735675790901945
11. Psychostimulant use disorder and the heart - Ovid — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/pdf/10.1111/add.14713
12. Cocaine Intoxication - an overview | ScienceDirect Topics — sciencedirect.com — https://sciencedirect.com/topics/medicine-and-dentistry/cocaine-intoxication
13. Emergency department management of methamphetamine toxicity - PubMed — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pubmed/37877728
14. Sympathomimetic Toxicity - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=6a084e257baa3e06c7b92a3b
15. Methamphetamine Toxicity(Archived) - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=69ae1e551a63f1308cdc47a4
16. Methamphetamine Toxicity - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK430895
17. Comprehensive review of cardiovascular toxicity of drugs and related agents — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC6033155
18. The ASAM/AAAP Clinical Practice Guideline on the Management of ... — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC11105801
19. Clinical Practice Guidelines for Assessment and Management of ... — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC10096213
20. Stimulant Drugs of Abuse and Cardiac Arrhythmias — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC8766923
21. [PDF] The ASAM/AAAP Clinical Practice Guideline on the ... - CDC Stacks — stacks.cdc.gov — https://stacks.cdc.gov/view/cdc/156927/cdc_156927_DS1.pdf
22. Common Substances of Abuse | Pediatrics In Review — publications.aap.org — https://publications.aap.org/pediatricsinreview/article/39/8/403/31962/Common-Substances-of-Abuse
23. Methamphetamine‐related cardiovascular diseases - Schwarzbach — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/abs/10.1002/ehf2.12572
24. Cocaine and cardiovascular toxicity - Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/abs/10.1080/1355621961000124676

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.